We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
CVS Group Plc | AQSE:CVSG.GB | Aquis Stock Exchange | Ordinary Share | GB00B2863827 | Ordinary Shares 20p |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
20.00 | 2.34% | 875.00 | 740.00 | 1,170.00 | 955.00 | 867.62 | 885.00 | 539 | 16:29:49 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCVSG
RNS Number : 7588X
CVS Group plc
22 December 2023
22 December 2023
CVS Group plc
("CVS" or the "Company")
Block Listing Application
CVS, one of the UK's leading providers of integrated veterinary services, announces that applications have been made to the London Stock Exchange for the admission of 410,000 of its ordinary shares of 0.2p each in the Company ("Ordinary Shares") to trading on AIM.
The 410,000 Ordinary Shares will be reserved under block listings with 350,000 Ordinary Shares to be added to the preexisting CVS Group SAYE Plan block listing and are to be issued in connection with the exercise of option awards under the terms of the Company's SAYE Plan.
The remaining 60,000 Ordinary Shares are to be added to the preexisting CVS Long Term Incentive Plan block listing and are to be issued in connection with the grant, vesting and/or exercise of awards under the terms of the Company's Long Term Incentive Plan ("LTIP").
When issued, the Ordinary Shares under the block listing will rank pari passu with the Company's existing issued Ordinary Shares. It is anticipated that the block-listed shares will be admitted on 28 December 2023.
Contacts:
CVS Group plc via Camarco
Richard Fairman, CEO
Scott Morrison, Company Secretary
Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418 8900
Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose
Berenberg (Joint Broker) +44 (0)20 3207 7800
Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser
Camarco (Financial PR)
Geoffrey Pelham-Lane +44 (0)7733 124 226
Ginny Pulbrook +44 (0)7961 315 138
About CVS Group plc ( www.cvsukltd.co.uk )
CVS Group is an AIM-listed provider of veterinary services in the UK, Australia, the Netherlands and the Republic of Ireland. CVS is focused on providing high quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.
The Group has c.500 veterinary practices across its four markets, including nine specialist referral hospitals and 39 dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties), Crematoria (providing pet cremation and clinical waste disposal for CVS and third-party practices), Buying Groups and the Group's online retail business ("Animed Direct").
The Group employs c.9,000 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ALSPPGQCPUPWUMP
(END) Dow Jones Newswires
December 22, 2023 02:48 ET (07:48 GMT)
1 Year CVS Chart |
1 Month CVS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions